Maya Martinez-Davis
Corporate Officer/Principal chez GSK PLC
Profil
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Postes actifs de Maya Martinez-Davis
| Sociétés | Poste | Début |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01/01/2020 |
Anciens postes connus de Maya Martinez-Davis
| Sociétés | Poste | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 23/01/2024 |
| MERCK KGAA | Corporate Officer/Principal | 01/08/2019 |
Formation de Maya Martinez-Davis
| St. Louis University | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
